SYSTEMIC TYPE EPSTEIN-BARR VIRUS-RELATED LYMPHOPROLIFERATIVE DISEASES IN CHILDREN AND YOUNG ADULTS: Challenges for Pediatric Hemato-Oncologists and Infectious Disease Specialists

REFERENCES

• Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343: 481–492
   PubMed Web of Science ®Google Scholar
• Rickenson A B, Kieff E. Epstein-Barr virus. Fields Virology4, DM Knipe, PM Howley. Lippincott, Williams & Wilkins, Philadelphia 2001; 2575–2627
   Google Scholar
• Imashuku S. Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol 2002; 44: 259–272
   PubMed Web of Science ®Google Scholar
• Kawa K. Diagnosis and treatment of Epstein-Barr virus-associated natural killer lymphoproliferative disease. Int J Hematol 2003; 78: 24–31
   PubMed Web of Science ®Google Scholar
• Kimura H, Morita M, Yabuta Y. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol 1999; 37: 132–136
   PubMed Web of Science ®Google Scholar
• Kasahara Y, Yachie A, Takei K. Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood 2001; 98: 1882–1888
   PubMed Web of Science ®Google Scholar
• Imashuku S, Hibi S, Tabata Y. Outcome of clonal hemophagocytic lymphohistiocytosis: analysis of 32 cases. Leuk Lymphoma 2000; 37: 577–584
   PubMed Web of Science ®Google Scholar
• Sumegi J, Huang D, Lanyi A. Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood 2000; 96: 3118–3125
   PubMed Web of Science ®Google Scholar
• Mroczek E C, Weisenburger D D, Grierson H L. Fatal infectious mononucleosis and virus-associated hemophagocytic syndrome. Arch Pathol Lab Med 1987; 111: 530–535
   PubMed Web of Science ®Google Scholar
• Janka G, Henter J-I, Imashuku S. Clinical aspects and therapy of hemophagocytic lymphohistiocytosis. Histiocytic Disorders of Children and Adults: Basic Science, Clinical Features and Therapy, S Weitzman, RM Egeler. Cambridge University Press, CambridgeUK 2005; 353–379
   Google Scholar
• Henter JI, Horne A, Arico M. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48: 124–131
   PubMed Web of Science ®Google Scholar
• Ishihara S, Okada S, Wakiguchi H. Chronic active Epstein-Barr virus infection in children in Japan. Acta Paediatr 1995; 84: 1271–1275
   PubMed Web of Science ®Google Scholar
• Murakami K, Ohsawa M, Hu SX. Large-vessel arteritis associated with chronic active Epstein-Barr virus infection. Arthritis Rheum 1998; 41: 369–373
   PubMed Web of Science ®Google Scholar
• Kimura H. Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Rev Med Virol 2006; 16: 251–261
   Google Scholar
• Okano M, Kawa K, Kimura H. Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol 2005; 80: 64–69
   PubMed Web of Science ®Google Scholar
• Wada T, Kurokawa T, Toma T. Immunophenotypic analysis of Epstein-Barr virus (EBV)-infected CD8(+) T cells in a patient with EBV-associated hemophagocytic lymphohistiocytosis. Eur J Haematol 2007; 79: 72–75
   PubMed Web of Science ®Google Scholar
• Lin M T, Chang H M, Huang C J. Massive expansion of EBV+monoclonal T cells with CD5 down regulation in EBV-associated haemophagocytic lymphohistiocytosis. J Clin Pathol 2007; 60: 101–103
   PubMed Web of Science ®Google Scholar
• Takahashi N, Chubachi A, Miura I. Lymphoma-associated hemophagocytic syndrome in Japan. Jpn J Clin Hematol 1999; 40: 542–549
   PubMedGoogle Scholar
• Yao M, Cheng A-L, Su I-J. Clinicopathological spectrum of haemophagocytic syndrome in Epstein-Barr virus associated T cell lymphoma. Br J Haematol 1994; 87: 535–543
   PubMed Web of Science ®Google Scholar
• Zareifer S, Geramizadeh B, Sharifian M. Simultaneous manifestation of fulminant infectious mononucleosis with B-cell non-Hodgkin's lymphoma. J Clin Oncol 2007; 25: 2051–2052
   Web of Science ®Google Scholar
• Matsumoto Y, Naniwa D, Banno S. The efficacy of therapeutic plasmapheresis for the treatment of fatal hemophagocytic syndrome: two case reports. Ther Apher 1998; 2: 300–304
   PubMedGoogle Scholar
• Milone M C, Tsai DE, Hodinka R L. Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood 2005; 105: 994–996
   PubMed Web of Science ®Google Scholar
• Imashuku S, Hibi S, Ohara T. Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Blood 1999; 93: 1869–1874
   PubMed Web of Science ®Google Scholar
• Minegishi M, Ohashi Y, Kumaki S. Successful umbilical cord blood transplantation from an unrelated donor for a patient with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Bone Marrow Transplant 2001; 27: 883–886
   PubMed Web of Science ®Google Scholar
• Ishimura M, Ohga S, Nomura A. Successful umbilical cord blood transplantation for severe chronic active Epstein-Barr virus infection after the double failure of hematopoietic stem cell transplantation. Am J Hematol 2005; 80: 207–212
   PubMed Web of Science ®Google Scholar
• Uehara T, Nakaseko C, Hara S. Successful control of Epstein-Barr virus (EBV)-infected cells by allogeneic nonmyeloablative stem cell transplantation in a patient with the lethal form of chronic active EBV infection. Am J Hematol 2004; 76: 368–372
   PubMed Web of Science ®Google Scholar